PharmaShots | Incisive News in 3 Shots

Subscribe Now

2L

Takeda's Alunbrig (brigatinib) Receives MHLW's Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC

Takeda's Alunbrig (brigatinib) Receives MHLW's Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC

January 22, 2021

$MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma$

MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or...

August 3, 2020

Merck's Keytruda Receives the NMPA's Approval as a 2L Treatment for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Merck's Keytruda Receives the NMPA's Approval as a 2L Treatment for Locally Advanced or Metastatic Esophageal Squamous Cell Carcin...

June 22, 2020

Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in P-II ORIENT-2 Study as 2L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in P-II ORIENT-2 Study as 2L Treatment for Advanced or Metastatic Esop...

May 14, 2020

Sanofi and Regeneron Report Results of Libtayo (cemiplimab) in a P-II Study as 2L Treatment for Advanced Basal Cell Carcinoma

Sanofi and Regeneron Report Results of Libtayo (cemiplimab) in a P-II Study as 2L Treatment for Advanced Basal Cell Carcinoma

May 6, 2020

Immunomedics' Trodelvy Receives the US FDA's Accelerated Approval for 2L Patients with Metastatic Triple-Negative Breast Cancer (TNBC)

Immunomedics' Trodelvy Receives the US FDA's Accelerated Approval for 2L Patients with Metastatic Triple-Negative Breast Cancer (T...

April 22, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us